PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
May 1, 2019, 00:00
10.1016/j.jval.2019.04.831
https://www.valueinhealthjournal.com/article/S1098-3015(19)31023-X/fulltext
Title :
PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)31023-X&doi=10.1016/j.jval.2019.04.831
First page :
Section Title :
Open access? :
No
Section Order :
10402